End-stage liver disease is marked by portal hypertension, systemic elevations in ammonia, and development of hepatocellular carcinoma (HCC). While these clinical consequences of cirrhosis are well described, it remains poorly understood whether hepatic insufficiency and the accompanying elevations in ammonia contribute to HCC carcinogenesis. Using preclinical models, we discovered that ammonia entered the cell through the transporter SLC4A11 and served as a nitrogen source for amino acid and nucleotide biosynthesis. Elevated ammonia promoted cancer stem cell properties in vitro and tumor initiation in vivo. Enhancing ammonia clearance reduced HCC stemness and tumor growth. In patients, elevations in serum ammonia were associated with an increased incidence of HCC. Taken together, this study forms the foundation for clinical investigations using ammonia-lowering agents as potential therapies to mitigate HCC incidence and aggressiveness.
The therapeutic landscape of hepatocellular carcinoma (HCC) has evolved with advances in systemic therapy and radiotherapy. Immune-checkpoint inhibitors, anti-angiogenic agents, stereotactic body radiotherapy (SBRT), and yttrium-90 transarterial radioembolization (TARE) have expanded treatment options across multiple stages of disease. Radiotherapy may complement systemic therapy through biological interactions involving tumor vasculature, hypoxia, and the immune microenvironment. These observations have generated growing interest in combined-modality therapy, although optimal approaches continue to be defined. In this review, we summarize the biological rationale and clinical evidence for integrating SBRT or TARE with targeted and immunotherapy-based regimens. We also highlight ongoing trials and emerging strategies for biologically informed therapy sensitization targeting tumor and immune-cell biology.